Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients

AIMS: This study aims to evaluate the impact of combinatorial pharmacogenomic (CPGx)-guided treatment (CPGT) on medication patterns, symptom remission and hospital stay in patients with schizophrenia. METHODS: and Kruskal-Wallis tests were used to compare the antipsychotics use rate and dosage between the two groups, respectively, and the generalized estimating equation was used to evaluate the effect of CPGx on the percentage change in the Positive and Negative Syndrome Scale (PANSS) score, response and hospital stay. RESULTS: This study included 895 hospitalization records from 494 patients with schizophrenia, with 331 in the CPGT and 564 in the TAU. CPGT added genotype-related prescriptions such as amisulpride, aripiprazole, risperidone and clozapine in the superior genotype subgroup (P < 0.05), reduced the dosage of risperidone in the slow metabolism subgroup, and increased the doses of clozapine, risperidone, quetiapine and olanzapine in the fast metabolism subgroup (P < 0.05). Compared with TAU, CPGT was associated with a higher percentage change in PANSS score during hospitalization (β = 6.79, 95% CI: 3.26-10.33) and a higher response rate (OR = 1.62; 95% CI, 1.21-2.16). Additionally, the hospital stay in the CPGT group was reduced by 4.80 (95% CI, 1.92-7.68) days. CONCLUSIONS: Our findings demonstrate that CPGx significantly improves treatment outcomes in hospitalized patients with schizophrenia, supporting that CPGx can guide treatment.